Hui Feng, MD, PhD
Associate Professor, Pharmacology, Physiology & Biophysics
Biography
Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.
Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.
The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.
Other Positions
- Member, BU-BMC Cancer Center, Boston University
- Member, Genome Science Institute, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Education
- Beijing Medical University, MD
- University of Georgia, PhD
- Peking Union Medical College, MS
Publications
- Published on 4/2/2024
AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep. 2024 Apr 02; 14(1):7526. PMID: 38565852.
Read at: PubMed - Published on 3/15/2024
Qin X, Lam A, Zhang X, Sengupta S, Iorgulescu JB, Ni H, Das S, Rager M, Zhou Z, Zuo T, Meara GK, Floru AE, Kemet C, Veerapaneni D, Kashy D, Lin L, Lloyd K, Kwok L, Smith KS, Nagaraju RT, Meijers R, Ceol C, Liu CT, Alexandrescu S, Wu CJ, Keskin DB, George RE, Feng H. CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. Sci Adv. 2024 Mar 15; 10(11):eadh9547. PMID: 38489372.
Read at: PubMed - Published on 2/7/2024
Xiao B, Landesman-Bollag E, Feng H. What value do zebrafish have to anticancer drug discovery? Expert Opin Drug Discov. 2024 Apr; 19(4):369-375. PMID: 38327017.
Read at: PubMed - Published on 3/23/2023
Laroche FJF, Li S, Shen N, Hwang SK, Nguyen G, Yu W, Wong CK, Quinton RJ, Berman JN, Liu CT, Singh A, Ganem NJ, Thiagalingam S, Feng H. S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. Cells. 2023 Mar 23; 12(7). PMID: 37048053.
Read at: PubMed - Published on 6/16/2022
Wang Y, Shen N, Spurlin G, Korm S, Huang S, Anderson NM, Huiting LN, Liu H, Feng H. a-Ketoglutarate-Mediated DNA Demethylation Sustains T-Acute Lymphoblastic Leukemia upon TCA Cycle Targeting. Cancers (Basel). 2022 Jun 16; 14(12). PMID: 35740646.
Read at: PubMed - Published on 2/8/2022
Kemet C, Hill E, Feng H. Fishing for drugs. Elife. 2022 02 08; 11. PMID: 35133278.
Read at: PubMed - Published on 11/16/2021
Shen N, Korm S, Karantanos T, Li D, Zhang X, Ritou E, Xu H, Lam A, English J, Zong WX, Liu CT, Shirihai O, Feng H. DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. Commun Biol. 2021 11 16; 4(1):1289. PMID: 34785772.
Read at: PubMed - Published on 8/2/2021
Friedlander JE, Shen N, Zeng A, Korm S, Feng H. Failure to Guard: Mitochondrial Protein Quality Control in Cancer. Int J Mol Sci. 2021 Aug 02; 22(15). PMID: 34361072.
Read at: PubMed - Published on 7/7/2021
Anderson NM, Qin X, Finan JM, Lam A, Athoe J, Missiaen R, Skuli N, Kennedy A, Saini AS, Tao T, Zhu S, Nissim I, Look AT, Qing G, Simon MC, Feng H. Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma. Cancer Res. 2021 Sep 01; 81(17):4417-4430. PMID: 34233924.
Read at: PubMed - Published on 5/20/2021
Miao KZ, Kim GY, Meara GK, Qin X, Feng H. Tipping the Scales With Zebrafish to Understand Adaptive Tumor Immunity. Front Cell Dev Biol. 2021; 9:660969. PMID: 34095125.
Read at: PubMed
View 41 more publications: View full profile at BUMC